ABX464降低ART抑制HIV感染者的总HIV储存库并抑制HIV转录起始
该研究基于ABIVAX-005试验子研究,9名ART抑制的HIV感染者每日口服150mg ABX464共4周。
要点
- 完整前病毒DNA和多聚腺苷酸化/multiply-spliced RNA未显著下降。
核心结论
- ABX464对ART抑制的HIV感染者具有降低总HIV DNA(可能包括完整前病毒)和抑制每前病毒HIV转录起始的双重作用。
研究设计与样本
- 来自ABIVAX-005临床试验(NCT02990325)的子研究,9名ART抑制的参与者每日接受150mg ABX464治疗4周,分析外周CD4+ T细胞。
主要发现
- 完整HIV DNA中位水平降低但无统计学意义(P不显著,中位倍数变化0.8)。
- 多聚腺苷酸化或多重剪接HIV RNA未见下降。
关键数值与推荐
- 未剪接HIV RNA中位变化:P不显著,中位倍数变化0.6。
临床怎么用
- ABX464可能作为减少HIV储存库和抑制转录的候选药物,但需在更大队列中研究长期给药以明确机制。
局限性
- 样本量小(9人),部分指标未达统计学显著性,需更大规模长期研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretroviral therapy (ART) intensification and disruption of latency have been suggested as strategies to eradicate HIV. ABX464 is a novel antiviral that inhibits HIV RNA biogenesis. We investigated its effect on HIV transcription and total and intact HIV DNA in CD4+ T cells from ART-suppressed participants enrolled in the ABIVAX-005 clinical trial (NCT02990325). METHODS: Peripheral CD4+ T cells were available for analysis from 9 ART-suppressed participants who were treated daily with 150 mg of ABX464 for 4 weeks. Total and intact HIV DNA and initiated, 5'elongated, unspliced, polyadenylated, and multiply-spliced HIV transcripts were quantified at weeks 0, 4, and 8 using ddPCR. RESULTS: We observed a significant decrease in total HIV DNA (P = .008, median fold change (mfc) = 0.8) and a lower median level of intact HIV DNA (P = not significant [n.s.], mfc = 0.8) after ABX464 treatment. Moreover, we observed a decrease in initiated HIV RNA per million CD4+ T cells and per provirus (P = .05, mfc = 0.7; P = .004, mfc = 0.5, respectively), a trend toward a decrease in the 5'elongated HIV RNA per provirus (P = .07, mfc = 0.5), and a lower median level of unspliced HIV RNA (P = n.s., mfc = 0.6), but no decrease in polyadenylated or multiply-spliced HIV RNA. CONCLUSIONS: In this substudy, ABX464 had a dual effect of decreasing total HIV DNA (and possibly intact proviruses) and HIV transcription per provirus. To further characterize its specific mechanism of action, long-term administration of ABX464 should be studied in a larger cohort. CLINICAL TRIALS REGISTRATION: NCT02990325.
引用
- Moron-Lopez S, Bernal S, Wong JK, et al. ABX464 Decreases the Total Human Immunodeficiency Virus (HIV) Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapy-Suppressed Individuals Living With HIV. Clin Infect Dis. 2022. PMID: 34436569. doi:10.1093/cid/ciab733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。